Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Patterns of pharmacotherapy for bipolar disorder: A GBC survey
Bipolar Disorders, Year 2023
Notification
URL copied to clipboard!
Description
Objectives: To understand treatment practices for bipolar disorders (BD), this study leveraged the Global Bipolar Cohort collaborative network to investigate pharmacotherapeutic treatment patterns in multiple cohorts of well-characterized individuals with BD in North America, Europe, and Australia. Methods: Data on pharmacotherapy, demographics, diagnostic subtypes, and comorbidities were provided from each participating cohort. Individual site and regional pooled proportional meta-analyses with generalized linear mixed methods were conducted to identify prescription patterns. Results: This study included 10,351 individuals from North America (n = 3985), Europe (n = 3822), and Australia (n = 2544). Overall, participants were predominantly female (60%) with BD-I (60%; vs. BD-II = 33%). Cross-sectionally, mood-stabilizing anticonvulsants (44%), second-generation antipsychotics (42%), and antidepressants (38%) were the most prescribed medications. Lithium was prescribed in 29% of patients, primarily in the Australian (31%) and European (36%) cohorts. First-generation antipsychotics were prescribed in 24% of the European versus 1% in the North American cohort. Antidepressant prescription rates were higher in BD-II (47%) compared to BD-I (35%). Major limitations were significant differences among cohorts based on inclusion/exclusion criteria, data source, and time/year of enrollment into cohort. Conclusions: Mood-stabilizing anticonvulsants, second-generation antipsychotics, and antidepressants were the most prescribed medications suggesting prescription patterns that are not necessarily guideline concordant. Significant differences exist in the prescription practices across different geographic regions, especially the underutilization of lithium in the North American cohorts and the higher utilization of first-generation antipsychotics in the European cohorts. There is a need to conduct future longitudinal studies to further explore these differences and their impact on outcomes, and to inform and implement evidence-based guidelines to help improve treatment practices in BD. © 2023 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.
Authors & Co-Authors
Strawbridge, Rebecca
United Kingdom, London
King's College London
Peters, Amy T.
United States, Boston
Harvard Medical School
Vieta, Eduard
Spain, Barcelona
Institut D'investigacions Biomèdiques August pi I Sunyer - Idibaps
Verdolini, Norma
Spain, Barcelona
Institut D'investigacions Biomèdiques August pi I Sunyer - Idibaps
Leboyer, Marion
France, Creteil
Institut Mondor de Recherche Biomédicale
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Nierenberg, Andrew Alan
United States, Boston
Harvard Medical School
Young, Allan H.
United Kingdom, London
King's College London
Ashton, Melanie Maree
Australia, Geelong
Barwon Health
Berk, Michael
Australia, Geelong
Barwon Health
Australia, Melbourne
Orygen Youth Health
Yatham, Lakshmi N.
Canada, Vancouver
The University of British Columbia
Overs, Bronwyn J.
Australia, Sydney
Neuroscience Research Australia
Fullerton, Janice M.
Australia, Sydney
Neuroscience Research Australia
Australia, Sydney
Unsw Sydney
Roberts, Gloria M.P.
Australia, Sydney
Unsw Sydney
Mitchell, Philip B.
Australia, Sydney
Unsw Sydney
Andreassen, Ole Andreas
Norway, Oslo
Oslo Universitetssykehus
Biernacka, Joanna M.
United States, Rochester
Mayo Clinic
France, Paris
Hôpital Fernand-widal
Frye, Mark A.
United States, Rochester
Mayo Clinic
Statistics
Citations: 2
Authors: 17
Affiliations: 17
Identifiers
Doi:
10.1111/bdi.13366
ISSN:
13985647
Research Areas
Mental Health
Substance Abuse
Study Design
Cross Sectional Study
Cohort Study
Study Approach
Quantitative
Mixed-methods
Participants Gender
Female